A Phase 3 interventional study of Standard of Care (SOC) Migraine Preventive Medication and Atogepant in Episodic Migraine, sponsored by Allergan. Completed at 112 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-06-15.
Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing atogepant in Migraine Disorders — 6 open to participants now, 7 under way, 4 of them phase 3. atogepant · Migraine Disorders.
Among the 21 studies testing atogepant in Migraine Disorders, this one is the 6th largest by enrollment, is one of 2 that started in 2018, is one of 15 in phase 3, and was the 2nd registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →6 of the 21 studies testing atogepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–70
AbbVie · Sites in United States, Canada, Denmark and 8 more countries
Ages 12–17
AbbVie · Sites in United States, Belgium, Canada and 13 more countries
Ages 6–17
AbbVie · Sites in United States, Belgium, Canada and 13 more countries
Ages 6–17
Konrad Peter Weber · Sites in Switzerland
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
atogepant: first FDA approval 2021 (QULIPTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 16 · Phase 4 4
First in 2016; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 744 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 468 across the 21 interventional studies. Of the 14 that completed or were terminated, 11 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 21 have an industry lead sponsor. The 5 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
55 studies in Migraine Disorders by AbbVie: 9 open now, 13 under way, 7 of them phase 3. Of 40 finished, 32 (80%) have results posted.
Among the 55 studies in Migraine Disorders by AbbVie, this one is the 13th largest by enrollment of the 41 interventional ones that give a count, is one of 3 that started in 2018, is one of 30 in phase 3, and was the 23rd registered.
AbbVie’s Migraine Disorders studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing atogepant in Migraine Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 55 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
This study will evaluate safety and tolerability of treatment with atogepant for the prevention of episodic migraine over the course of one year.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral standard of care (SOC) medication recognized as safe and effective for the prevention of migraine, based on investigator's judgement in consultation with the participant.
Drug: Standard of Care (SOC) Migraine Preventive Medication
Atogepant 60 mg tablet taken orally, once daily for 52 weeks.
Drug: Atogepant
Standard of care medication selected based on investigator's judgement, recognized as safe and effective for the prevention of migraine.
Atogepant tablets taken orally, once daily for 52 weeks.
Percentage of Participants With at Least 1 Treatment Emergent Adverse Event (TEAE)
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE is an AE that occurs or worsens after receiving investigational study drug.
Time frame: From first dose up to the end of study (median treatment of 52 weeks) + 4 weeks follow-up
Percentage of Participants With Clinically Significant Laboratory Values as Assessed by the Investigator
Laboratory tests included tests of hematology, chemistry, and urinalysis. The investigator determined if the results were potentially clinically significant (PCS). Only categories with at least one participant are reported.
Time frame: From first dose up to the end of study (median treatment of 52 weeks) + 4 weeks follow-up
Percentage of Participants With Clinically Significant Electrocardiogram (ECG) Findings as Assessed by the Investigator
A standard 12-lead ECG was performed. The investigator determined if the result was potentially clinically significant. Only categories with at least one participant are reported.
Time frame: Up to Week 52
Percentage of Participants With Clinically Significant Vital Sign Measurements as Assessed by the Investigator
Vital sign measurements included sitting and standing blood pressure (BP), sitting and standing pulse rate, respiratory rate, temperature, and body weight. The investigator determined if the results were clinically significant. Only categories with at least one participant are reported.
Time frame: From first dose up to the end of study (median treatment of 52 weeks + 4 weeks follow-up)
Number of Participants With Most Severe Columbia-Suicide Severity Rating Scale (C-SSRS) Assessing Suicidal Ideation or Suicidal Behavior
The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. (Minimum total score 0, maximum total score 5; higher total scores indicate more suicidal ideation and/or suicidal behavior). Only the most severe suicidal ideation and the most severe suicidal behavior counted during the treatment period for at least 1 participant are reported.
Time frame: Up to Week 52
| Milestone | Oral SOC Migraine Preventive Medication | Atogepant 60 mg |
|---|---|---|
| Started | 198 | 546 |
| Safety population; received treatment | 196 | 543 |
| Entered safety follow-up | 159 | 472 |
| Completed | 136 | 373 |
| Not completed | 62 | 173 |
| Withdrew: Adverse event | 5 | 31 |
| Withdrew: Lack of efficacy | 2 | 5 |
| Withdrew: Withdrawal by subject | 29 | 75 |
| Withdrew: Lost to follow-up | 16 | 23 |
| Withdrew: Pregnancy | 2 | 4 |
| Withdrew: Protocol deviation | 7 | 31 |
| Withdrew: Non-compliance with study drug | 1 | 3 |
| Withdrew: Reason not specified | 0 | 1 |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE is an AE that occurs or worsens after receiving investigational study drug.
| percentage of participants | Oral SOC Migraine Preventive Medication | Atogepant 60 mg |
|---|---|---|
| Percentage of Participants With at Least 1 Treatment Emergent Adverse Event (TEAE) | 78.6 | 67.0 |
Laboratory tests included tests of hematology, chemistry, and urinalysis. The investigator determined if the results were potentially clinically significant (PCS). Only categories with at least one participant are reported.
| percentage of participants | Oral SOC Migraine Preventive Medication | Atogepant 60 mg |
|---|---|---|
| Eosinophils Absolute Cell Count (10^9/liter (L)): >2.0 × upper limit of normal (ULN) | 0.0 | 0.6 |
| Hematocrit (RATIO): <0.9 × lower limit of normal (LLN) | 1.6 | 1.7 |
| Hematocrit (RATIO): >1.1 × ULN | 0.0 | 0.2 |
| Hemoglobin (gram (g)/L): <0.9 × LLN | 3.3 | 3.1 |
| Lymphocytes Absolute Cell Count (10^9/L): <0.7 × LLN | 0.5 | 0.8 |
| Lymphocytes Absolute Cell Count (10^9/L): >1.3 × ULN | 0.5 | 0.2 |
| Monocytes Absolute Cell Count (10^9/L): <0.5 × LLN | 1.1 | 0.2 |
| Neutrophils Absolute Cell Count (10^9/L): <0.7 × LLN | 2.1 | 2.3 |
| Neutrophils Absolute Cell Count (10^9/L): >1.3 × ULN | 4.8 | 7.1 |
| Platelet Count (Thrombocytes) (10^9/L): >1.5 × ULN | 0.5 | 0.2 |
| Red Blood Cell Count (10^12/L): <0.9 × LLN | 3.2 | 2.1 |
| White Blood Cell Count (10^9/L): <0.9 × LLN | 3.2 | 4.6 |
| White Blood Cell Count (10^9/L): >1.5 × ULN | 1.1 | 0.6 |
| Alanine Aminotransferase (serum glutamic-pyruvic transaminase (SGPT)) (Unit (U)/L): ≥3.0 × ULN | 1.6 | 1.9 |
| Aspartate Aminotransferase (serum glutamic-oxaloacetic transaminase (SGOT)) (U/L): ≥3.0 × ULN | 2.1 | 1.5 |
| Bicarbonate (HCO3) (millimole (mmol)/L): <0.9 × LLN | 1.6 | 0.8 |
| Bilirubin, Total (micromole (umol)/L): ≥1.5 × ULN | 0.0 | 0.8 |
| Blood Urea Nitrogen (mmol/L): >1.5 × ULN | 0.5 | 0.4 |
| Creatine Kinase (U/L): >2.0 × ULN | 14.1 | 9.1 |
| Creatinine (umol/L): >1.5 × ULN | 1.1 | 0.4 |
| Glomerular Filtration Rate(GFR) Estimated Calculation:<60 milliliter(mL)/minute(min)/1.73 meter(m)^2 | 15.2 | 15.9 |
| Glucose, Non-fasting (mmol/L): <0.8 × LLN | 5.3 | 4.2 |
| Glucose, Non-fasting (mmol/L): >2.0 × ULN | 2.1 | 0.8 |
| Lactate Dehydrogenase (U/L): >3.0 × ULN | 0.0 | 0.4 |
| Phosphorus (mmol/L): <0.9 × LLN | 2.1 | 2.6 |
| Phosphorus (mmol/L): >1.1 × ULN | 0.0 | 0.2 |
| Potassium (mmol/L): <0.9 × LLN | 1.1 | 0.8 |
| Potassium (mmol/L): >1.1 × ULN | 4.3 | 5.1 |
| Protein, Total (g/L): <0.9 × LLN | 3.2 | 1.5 |
| Uric Acid (Urate) (umol/L): >1.2 × ULN | 1.6 | 1.1 |
| Urine Glucose At Least 1+ | 4.3 | 3.0 |
| Urine Protein: At Least 1+ | 26.2 | 27.4 |
A standard 12-lead ECG was performed. The investigator determined if the result was potentially clinically significant. Only categories with at least one participant are reported.
| percentage of participants | Oral SOC Migraine Preventive Medication | Atogepant 60 mg |
|---|---|---|
| PR Interval, Single Beat millisecond (msec): ≥250 | 0.0 | 0.2 |
| QTcB Interval, Single Beat (msec): Increase >60 from Baseline (BL) | 0.6 | 0.4 |
| QTcF Interval, Single Beat (msec): Increase >60 from BL | 0.6 | 0.0 |
Vital sign measurements included sitting and standing blood pressure (BP), sitting and standing pulse rate, respiratory rate, temperature, and body weight. The investigator determined if the results were clinically significant. Only categories with at least one participant are reported.
| percentage of participants | Oral SOC Migraine Preventive Medication | Atogepant 60 mg |
|---|---|---|
| Systolic Blood Pressure (SBP) Sitting (millimeter of mercury(mmHg)):≤90 and Decrease of ≥20 from BL | 3.7 | 2.6 |
| SBP Sitting (mmHg): ≥180 and Increase of ≥20 from BL | 0.0 | 0.4 |
| SBP Standing (mmHg): ≤90 and Decrease of ≥20 from BL | 5.8 | 3.4 |
| SBP Standing (mmHg): ≥180 and Increase of ≥20 from BL | 0.0 | 0.6 |
| Standing - Sitting SBP (mmHg): ≤-20 | 13.8 | 11.4 |
| Diastolic Blood Pressure (DBP) Sitting (mmHg): ≤50 and Decrease of ≥15 from BL | 3.2 | 0.6 |
| DBP Sitting (mmHg): ≥105 and Increase of ≥15 from BL | 1.1 | 2.3 |
| DBP Standing (mmHg): ≤50 and Decrease of ≥15 from BL | 1.1 | 0.9 |
| DBP Standing (mmHg): ≥105 and Increase of ≥15 from BL | 5.8 | 4.0 |
| Standing - Sitting DBP (mmHg): ≤-15 | 10.1 | 8.7 |
| Pulse Rate (PR) Sitting (beats/min): ≤50 and Decrease of ≥15 from BL | 1.6 | 1.1 |
| PR Standing (beats/min): ≤50 and Decrease of ≥15 from BL | 0.0 | 0.2 |
| PR Standing (beats/min): ≥120 and Increase of ≥15 from BL | 2.6 | 1.3 |
| Standing - Sitting PR (beats/min): ≥25 | 6.3 | 10.0 |
| Weight (kg): Decrease of ≥7% from BL | 14.7 | 24.1 |
| Weight (kg): Increase of ≥7% from BL | 12.6 | 7.3 |
The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. (Minimum total score 0, maximum total score 5; higher total scores indicate more suicidal ideation and/or suicidal behavior). Only the most severe suicidal ideation and the most severe suicidal behavior counted during the treatment period for at least 1 participant are reported.
| Participants | Oral SOC Migraine Preventive Medication | Atogepant 60 mg |
|---|---|---|
| Suicidal Ideation (SI): Wish to be Dead | 4 | 0 |
| SI: Non-Specific Active Suicidal Thoughts | 1 | 2 |
| SI: Active SI with Some Intent to Act, Without Specific Plan | 0 | 1 |
| SI: Active SI With Specific Plan and Intent | 0 | 2 |
| Suicidal Behavior (SB): Actual Attempt | 0 | 2 |
Collected over From first dose up to the end of study (median treatment of 52 weeks + 4 weeks follow-up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oral SOC Migraine Preventive Medication | 0/198 (0%) | 7/196 (3.6%) | 91/196 (46.4%) |
| Atogepant 60 mg | 2/546 (0.4%) | 24/543 (4.4%) | 197/543 (36.3%) |
| Event | Oral SOC Migraine Preventive Medication | Atogepant 60 mg |
|---|---|---|
| Non-cardiac chest painGeneral disorders | 2/196 | 0/543 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 1/196 | 0/543 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/196 | 0/543 |
| Colon cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/196 | 0/543 |
| Device malfunctionProduct Issues | 1/196 | 0/543 |
| Suicidal ideationPsychiatric disorders | 1/196 | 0/543 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/172 | 1/479 |
| Ovarian cystReproductive system and breast disorders | 0/172 | 1/479 |
| Uterine haemorrhageReproductive system and breast disorders | 0/172 | 1/479 |
| VertigoEar and labyrinth disorders | 0/196 | 1/543 |
| Event | Oral SOC Migraine Preventive Medication | Atogepant 60 mg |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 24/196 | 56/543 |
| DizzinessNervous system disorders | 22/196 | 17/543 |
| ConstipationGastrointestinal disorders | 6/196 | 39/543 |
| NauseaGastrointestinal disorders | 12/196 | 34/543 |
| FatigueGeneral disorders | 12/196 | 14/543 |
| ParaesthesiaNervous system disorders | 12/196 | 8/543 |
| Weight increasedInvestigations | 11/196 | 7/543 |
| AnxietyPsychiatric disorders | 11/196 | 15/543 |
| Urinary tract infectionInfections and infestations | 9/196 | 28/543 |
| NasopharyngitisInfections and infestations | 10/196 | 24/543 |
Safety Population included all participants who received ≥1 dose of study intervention.
| Age, Continuous(years) | Oral SOC Migraine Preventive Medication | Atogepant 60 mg | Total |
|---|---|---|---|
| Mean | 41.1 ± 12.09 | 42.5 ± 12.03 | 42.2 ± 12.05 |
| Sex: Female, Male(Participants) | Oral SOC Migraine Preventive Medication | Atogepant 60 mg | Total |
|---|---|---|---|
| Female | 172 | 479 | 651 |
| Male | 24 | 64 | 88 |
| Ethnicity (NIH/OMB)(Participants) | Oral SOC Migraine Preventive Medication | Atogepant 60 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 29 | 83 | 112 |
| Not Hispanic or Latino | 166 | 460 | 626 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Oral SOC Migraine Preventive Medication | Atogepant 60 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 3 | 3 |
| Asian | 5 | 12 | 17 |
| Native Hawaiian or Other Pacific Islander | 2 | 2 | 4 |
| Black or African American | 38 | 100 | 138 |
| White | 145 | 416 | 561 |
| More than one race | 5 | 10 | 15 |
| Unknown or Not Reported | 1 | 0 | 1 |
Showing the first 100 of 112 sites. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2018 to primary completion in May 2020, 19 months.
Results were first posted in Jun 2021, 1 year after primary completion.
Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 19 months is close to that.
Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atogepant